# Relates to the availability of opioid reversal agents

**Bill ID:** S8991AA
**Session:** 2024
**Sponsor:** Pete Harckham
**Status:** In Senate Committee
**PDF:** [S8991AA PDF](https://legislation.nysenate.gov/pdf/bills/2024/S8991AA)

## Summary

Relates to the availability of opioid reversal agents; requires the department of health to make available any formulation and dosage of opioid reversal agents approved by the federal food and drug administration.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  8991--A
 
  I N  S E N A T E
 
  April 8, 2024
  ___________
 
 Introduced by Sens. HARCKHAM, ASHBY, COONEY, GALLIVAN, OBERACKER -- read
  twice  and  ordered  printed,  and when printed to be committed to the
  Committee on Alcoholism  and  Substance  Use  Disorders  --  committee
  discharged, bill amended, ordered reprinted as amended and recommitted
  to said committee
 
 AN  ACT  to  amend  the mental hygiene law and the public health law, in
  relation to the availability of opioid reversal agents
 
  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
  Section 1. Subdivision (l) of section 19.09 of the mental hygiene law,
 as  added  by  chapter  434  of  the laws of 2021, is amended to read as
 follows:
  (l)(1) The office, in consultation  with  the  department  of  health,
 shall  maintain  on  its  website  a publicly available directory of all
 distributors of opioid [antagonists]  REVERSAL  AGENTS  to  the  public,
 including  but  not limited to, pharmacies, prevention programs and not-
 for-profits. As used in this subdivision, the following terms shall have
 the following meanings:
  (i) "Opioid" means  an  opiate  as  defined  in  section  thirty-three
 hundred two of the public health law.
  (ii)  "Opioid  [antagonist]  REVERSAL AGENTS" means a federal food and
 drug administration-approved drug that, when  administered,  negates  or
 neutralizes in whole or in part the pharmacological effects of an opioid
 in  the  body.  The  [opioid  antagonist shall be limited to naloxone or
 other medications approved by the department of health for this purpose]
 DEPARTMENT OF HEALTH SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE  OF
 OPIOID  REVERSAL  AGENTS  THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION.
  (III) "PURCHASER"  MEANS  ANY  COMMUNITY  ORGANIZATION,  MUNICIPALITY,
 PHARMACY, MEDICAL FACILITY, HOSPITAL, OR ANY OTHER ENTITY, THAT ACCESSES
 OPIOID REVERSAL DRUGS THROUGH THE NEW YORK STATE STANDING ORDER.
  (2)  The  directory  required by this subdivision shall include and be
 searchable by the following information:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD11983-07-4
 S. 8991--A  2
 
  (i) addresses of each distributor  of  opioid  [antagonists]  REVERSAL
 AGENTS;
  (ii)  contact  information,  such as phone numbers or email addresses,
 for each distributor;
  (iii) services offered by each distributor at each  location  if  more
 than  one,  as  well as information providing which opioid [antagonists]
 REVERSAL AGENTS are currently available at each distributor;
  (iv) special populations served;
  (v) insurance providers accepted;
  (vi) hours of operation of each distributor;
  (vii) contact information of opioid addiction prevention programs; and
  (viii) any other information the commissioner deems necessary.
  (3) The office may  utilize  an  existing  directory  to  satisfy  the
 requirements of this subdivision.
  (4) THE OFFICE SHALL ALLOW FOR CHOICE OF ANY FORMULATION AND DOSAGE OF
 OPIOID  REVERSAL  AGENTS  THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION  IN  THE  PURCHASE,  DISTRIBUTION  OR  AUTHORIZATION  TO
 PRESCRIBE OR DISPENSE SUCH PRODUCTS. THE DEPARTMENT SHALL COVER THE COST
 OF  ANY  FORMULATION AND/OR DOSAGE OF ANY FEDERAL FOOD AND DRUG ADMINIS-
 TRATION-APPROVED NASAL NALOXONE PRODUCT.  ANY OTHER PRODUCT  WHERE  THE
 COST  EXCEEDS  THAT  OF HIGHEST-PRICED NASAL NALOXONE PRODUCT, THAT COST
 OVERRUN SHALL BE BORNE BY THE PURCHASER.
  ยง 2. Subparagraph (i) of paragraph (a) of  subdivision  3  of  section
 3309  of  the public health law, as amended by chapter 42 of the laws of
 2014, is amended to read as follows:
  (i) "Opioid [antagonist] REVERSAL AGENTS" means a drug approved by the
 Food  and  Drug  Administration  that,  when  administered,  negates  or
 neutralizes in whole or in part the pharmacological effects of an opioid
 in  the  body.  ["Opioid antagonist reversal agents" shall be limited to
 naloxone and other medications  approved  by  the  department  for  such
 purpose]  THE DEPARTMENT SHALL MAKE AVAILABLE ANY FORMULATION AND DOSAGE
 OF OPIOID REVERSAL AGENTS THAT ARE APPROVED BY THE FEDERAL FOOD AND DRUG
 ADMINISTRATION.
  ยง 3. Section 3309 of the public health law is amended by adding a  new
 subdivision 9 to read as follows:
  9.  ANY  PURCHASE, DISTRIBUTION OR AUTHORIZATION TO PRESCRIBE PURSUANT
 TO THIS SECTION BY THE COMMISSIONER SHALL ALLOW FOR CHOICE OF ANY FORMU-
 LATION OR DOSAGE THAT IS APPROVED BY THE FEDERAL FOOD AND DRUG  ADMINIS-
 TRATION.  THE  DEPARTMENT SHALL COVER THE COST OF ANY FORMULATION AND/OR
 DOSAGE OF ANY FEDERAL FOOD AND DRUG ADMINISTRATION-APPROVED NASAL NALOX-
 ONE PRODUCT.  ANY OTHER PRODUCT WHERE THE COST EXCEEDS THAT OF  HIGHEST-
 PRICED  NASAL  NALOXONE PRODUCT, THAT COST OVERRUN SHALL BE BORNE BY THE
 PURCHASER.
  ยง 4. This act shall take effect immediately.